# Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

> **NCT02919111** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 299 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ga-68 labeled PSMA-11 PET

## Key facts

- **NCT ID:** NCT02919111
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-23
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919111, "Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02919111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*